In the past 20 years, new insights into the genomic pathogenesis of prostate cancer have been provided. Large-scale integrative genomics approaches enabled researchers to characterize the genetic and epigenetic landscape of prostate cancer and to define different molecular subclasses based on the combination of genetic alterations, gene expression patterns and methylation profiles. Several molecular drivers of prostate cancer have been identified, some of which are different in men of different races. However, the extent to which genomics can explain racial disparities in prostate cancer outcomes is unclear. Future collaborative genomic studies overcoming the underrepresentation of non-white patients and other minority populations are essential.
Nature reviews. Urology. 2022 Aug 09 [Epub ahead of print]
Camilo Arenas-Gallo, Jude Owiredu, Ilon Weinstein, Patrick Lewicki, Spyridon P Basourakos, Randy Vince, Bashir Al Hussein Al Awamlh, Fredrick R Schumacher, Daniel E Spratt, Christopher E Barbieri, Jonathan E Shoag
Department of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA., Department of Urology, NewYork-Presbyterian Hospital, Weill Cornell Medicine, New York, NY, USA., Department of Urology, University of Michigan, Ann Arbor, MI, USA., Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA., Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA., Department of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA. .